Gangolli Julian S Form 3 GW PHARMACEUTICALS / Julian S Gangolli ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gangolli Julian S

(Last)

(First)

(Middle)

SOVEREIGN HOUSE, VISION PARK, HISTON

(Street)

CAMBRIDGE

CB24 9BZ

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2018

3. Issuer Name and Ticker or Trading Symbol
GW PHARMACEUTICALS PLC [ GWPH ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
President, North America

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares⁽¹⁾	101,292	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options⁽²⁾	06/24/2019	12/24/2019	Ordinary Shares	10,609	0.0013⁽³⁾	D
Stock Options⁽²⁾	06/24/2018	06/24/2025	Ordinary Shares	75,369	8.7364⁽³⁾	D
Stock Options⁽²⁾	02/15/2019	03/15/2020	Ordinary Shares	27,419	0.0013⁽³⁾	D
Stock Options⁽²⁾	02/15/2020	03/15/2021	Ordinary Shares	27,420	0.0013⁽³⁾	D
Stock Options⁽²⁾	02/15/2019	03/15/2020	Ordinary Shares	365,591	0.0013⁽³⁾	D
Stock Options⁽²⁾	02/15/2019	02/15/2026	Ordinary Shares	192,755	3.3461⁽³⁾	D
Stock Options⁽²⁾	01/06/2019	03/15/2020	Ordinary Shares	10,788	0.0013⁽³⁾	D
Stock Options⁽²⁾	01/06/2020	03/15/2021	Ordinary Shares	10,788	0.0013⁽³⁾	D
Stock Options⁽²⁾	01/06/2021	03/15/2022	Ordinary Shares	10,788	0.0013⁽³⁾	D
Stock Options⁽²⁾	01/06/2020	03/15/2021	Ordinary Shares	143,832	0.0013⁽³⁾	D
Stock Options⁽²⁾⁽⁴⁾	01/06/2020	01/06/2027	Ordinary Shares	87,660	9.8117	D
Stock Options⁽²⁾	02/26/2019	03/15/2020	Ordinary Shares	11,262	0.0013⁽³⁾	D
Stock Options⁽²⁾	02/26/2020	03/15/2021	Ordinary Shares	11,262	0.0013⁽³⁾	D
Stock Options⁽²⁾	02/26/2021	03/15/2022	Ordinary Shares	11,262	0.0013⁽³⁾	D
Stock Options⁽²⁾	02/26/2022	03/15/2023	Ordinary Shares	11,262	0.0013⁽³⁾	D
Stock Options⁽²⁾	02/26/2021	03/15/2022	Ordinary Shares	150,156	0.0013⁽³⁾	D
Stock Options⁽²⁾⁽⁴⁾	02/26/2021	02/26/2028	Ordinary Shares	74,088	9.6092	D

Explanation of Responses:

1. Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer.

2. Granted pursuant to the Issuer's Long-Term Incentive Plan.

3. Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.302 U.S. Dollars as of September 28, 2018.

4. The reported options are options to purchase ADSs.

Remarks:

	/s/ Julian Gongolli	10/01/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Gangolli Julian S Form 3GW PHARMACEUTICALS / Julian S Gangolli ownership change